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Abstract
Ceramide is characterized as a second messenger of apoptosis induced by various agents such as tumor necrosis factor
(TNF-K), Fas ligand, hydrogen peroxide, heat shock and ionizing radiation. In this study, we investigated the mechanism of
ceramide-induced apoptosis using a human neuroblastoma cell line, SK-N-MC. N-Acetyl-sphingosine (C2-ceramide), a cell-
permeable ceramide analogue, was able to induce apoptosis in SK-N-MC cells as estimated by DNA fragmentation and
chromatin condensation. C2-ceramide-induced DNA fragmentation was blocked by caspase inhibitor (Z-Asp-CH2-DCB).
An increase in caspase-3 (CPP32)-like protease activity was evident during C2-ceramide-induced apoptosis, suggesting that
caspases are involved in this apoptosis. Moreover, enzymatic cleavage of VDVAD-AFC and LEHD-AFC (specific substrates
for caspase-2 and -9, respectively) was increased by treatment with C2-ceramide. To elucidate which types of caspase are
activated in C2-ceramide-treated cells, we performed Western blot analysis using antibodies against each isoform. Both
proforms of caspase-2 and -3 were decreased in response to C2-ceramide in a time-dependent manner. Mitochondrial
cytochrome c is also time-dependently released into the cytosol in response to treatment with C2-ceramide. Addition of
cytochrome c into the S-100 fractions prepared from SK-N-MC cells could activate caspase-2 in cell-free systems. These
results suggest the possibility that cytochrome c released to the cytosol can activate caspases (caspase-9, -3, and -2) during
C2-ceramide-induced apoptosis of SK-N-MC cells. ß 1999 Elsevier Science B.V. All rights reserved.
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1. Introduction
Sphingolipids have been known to be structural
lipids that are constituents of the plasma membrane;
they are also, however, widely recognized as intra-
cellular second messengers. Signals via cell-surface
receptors such as tumor necrosis factor (TNF) or
Fas (CD95/Apo1), and various stress stimuli such
as X-rays, hydrogen peroxide, heat shock, or ultra-
violet-B irradiation activate sphingomyelinase
(SMase) and then generate ceramide through the hy-
drolysis of sphingomyelin. The production results in
cell death by means of apoptosis [1^3]. Ceramide is
therefore considered to be an apoptotic second mes-
senger, since synthetic cell-permeable ceramide can
also induce apoptosis in hematocytes [4] and neuro-
nal cells [5,6]. In contrast, cell-permeable ceramide
has an anti-apoptotic e¡ect to protect the cells
against glutamate or amyloid L-peptide toxicity and
nerve growth factor deprivation [7,8]. These results
suggest that di¡erent signal transductions exist
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downstream from ceramide production in each neu-
ronal cell type.
Genetics studies in Caenorhabditis elegans have
identi¢ed the ced-3 gene, which is required for all
developmentally programmed cell deaths [9]. First,
the cysteine protease interleukin-1L converting en-
zyme (ICE) was identi¢ed as the mammalian Ced-3
homologue [10]. Subsequently, 13 additional mam-
malian Ced-3-related cysteine proteases have been
isolated and termed as caspases that play a central
role in the execution of apoptosis. All caspase family
genes encode proenzyme forms that require proteo-
lytic cleavage for activation. From an analysis of the
caspase-1 (ICE)- and caspase-3 (CPP32)-de¢cient
mouse, each caspase has been shown to play a di¡er-
ent role in di¡erent cells, tissues, or apoptotic stimuli
[11,12]. Nedd-2, murine caspase-2 (Ich-1), has been
isolated and shown to be highly expressed during
early embryonic brain development but not in the
adult brain [13,14]. A decrease in caspase-2 levels
in response to antisense technology delays apoptosis
induced by trophic factor deprivation in neuronal
cell line, PC12 cells [15]. The involvement of casp-
ase-2 in other stimulus-induced neuronal apoptosis
compared to that of caspase-3 in apoptosis by multi-
ple apoptotic stimuli such as TNF-K, Fas, granzyme
B, and ceramide, however, remains unknown [16^22].
In the current study, we therefore investigated the
involvement of caspases, particular caspase-9 and
caspase-3-like proteases, in ceramide-induced apop-
tosis in a human neuroblastoma cell line, SK-N-MC.
2. Materials and methods
2.1. Materials
SK-N-MC cells were obtained from the American
Type Culture Collection (USA). N-Acetyl-sphingo-
sine (C2-ceramide), sphingosine, and sphingomyeli-
nase (from Staphylococcus aureus) were purchased
from Sigma (USA). The cytotoxicity Detection Kit
(lactate dehydrogenase (LDH)) and high ¢delity
PCR system were obtained from Boehringer Mann-
heim (UK). Benzyloxycarbonyl-Asp-CH2OC(O)-2,
6-dichlorobenzene (Z-Asp-CH2-DCB), N-acetyl-
Asp-Glu-Val-Asp-4-methylcoumaryl-7-amide (Ac-
DEVD-MCA), and N-acetyl-Tyr-Val-Ala-Asp-4-
methylcoumaryl-7-amide (Ac-YVAD-MCA) were
from Peptide Institute (Japan). Caspase-2 and casp-
ase-9 £uorometric protease assay kits were from
MBL (Japan). Oligo(dT)12ÿ18 primer and superscript
reverse transcriptase (RT) were obtained from Gibco
BRL (USA). Anti-ICE and CED-3 homologue 1
(anti-Ich-1; caspase-2) antibody, anti-cysteine pro-
tease p32 (anti-CPP32; caspase-3) antibody, anti-K-
tubulin antibody, and anti-poly(ADP-ribose) poly-
merase (anti-PARP) antibody (clone C-2-10) were
from Santa Cruz (USA), Transduction Laboratories
(USA), Seikagaku (Japan) and Clontech (USA), re-
spectively. Anti-caspase-6, -7, -8, and -10 antibodies
and anti-cytochrome c antibodies (7H8.2C12 and
6H2.B4) were from Pharmingen (USA). The TNT
T7 Coupled Reticulocyte Lysate System was pur-
chased from Promega (USA).
2.2. Cell culture
SK-N-MC cells were maintained in minimum es-
sential medium supplemented with 10% fetal calf se-
rum (FCS) in a humidi¢ed incubator containing 5%
CO2.
2.3. LDH leakage assay
Cell death was estimated by the LDH leakage
method using a Cytotoxicity Detection Kit (Boehr-
inger Mannheim) according to the manufacturer’s
protocol. Cells were seeded at 1.5U105/well in tripli-
cate in 12-well plates for 48 h prior to treatment with
C2-ceramide (0^20 WM) for 24 h in serum-free me-
dium. LDH activity was measured as optimal density
at 492 nm, and LDH leakage (%) was de¢ned as the
ratio of LDH activity in the culture medium to the
total activity (% = (extracellular activity)/(extracellu-
lar activity+remaining cellular activity)).
2.4. Apoptosis assay
For the DNA fragmentation assay, the cells were
lysed in a lysis bu¡er (10 mM Tris-HCl (pH 7.4),
5 mM EDTA, 0.5% Triton X-100) and incubated
for 20 min at 4‡C. The samples were centrifuged at
27 000Ug for 15 min at 4‡C. The supernatants were
incubated with 40 Wg/ml proteinase K for 30 min at
37‡C and extracted with an equal volume of phenol,
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phenol/chloroform (v/v; 1:1), and chloroform. The
DNA was precipitated from the supernatants with
a 1/10 volume of 3 M sodium acetate and 2.5 vols.
of ethanol and then treated with 40 Wg/ml RNase A
for 1 h at 37‡C. The recovered DNA was then ana-
lyzed by electrophoresis on a 1.8% agarose gel and
visualized with ethidium bromide. For £uorescent
nuclei staining, the cells were harvested and ¢xed
for 20 min in PBS containing 1% glutaraldehyde.
After ¢xation, the cells were washed four times
with PBS and then stained with 1 mM Hoechst
33258, and the nuclei were visualized by £uorescent
microscopy as described in [23].
2.5. Measurement of caspase activity
The cells were collected, washed with PBS, and
suspended in 50 mM Tris-HCl (pH 7.4), 1 mM
EDTA, and 10 mM EGTA. After the addition of
10 WM digitonin, the cells were incubated at 37‡C
for 10 min and then centrifuged at 15 000 rpm for
20 min. The clear lysate (50 Wg of protein) was in-
cubated at 37‡C with 50 WM DEVD-MCA for 30 min
or 50 WM YVAD-MCA for 1 h. The amounts of
released 7-amino-4-methylcoumarin (AMC) were
measured with a £uorescence spectrophotometer (Hi-
tachi F-2000) with excitation at 380 nm and emission
at 460 nm. Caspase-2 and -9 activities were measured
using caspase-2 and caspase-9 £uorometric protease
assay kits. The assay for caspase-2 or caspase-9 ac-
tivity is based on detection of cleavage of substrate
VDVAD-7-amino-4-tri£uoromethylcoumarin (AFC)
or LEHD-AFC. The amounts of released AFC
were measured with a £uorescence spectrophotome-
ter (Molecular Devices) with excitation at 400 nm
and emission at 505 nm.
2.6. RT-PCR analysis
Total RNA was prepared from SK-N-MC cells
and Jurkat cells using the acid guanidium thiocya-
nate-phenol-chloroform extraction method. Total
RNA (2 Wg) was reverse-transcribed in a mixture
containing oligo(dT)12ÿ18 primer (Gibco BRL) and
superscript reverse transcriptase (Gibco BRL). PCR
was carried out in a 20 Wl reaction volume containing
2 Wl of cDNA mixture, 1UExpand high ¢delity bu¡-
er containing 1.5 mM MgCl2, 200 WM each dNTP,
200 WM each primer, and 0.7 U of high ¢delity PCR
system enzyme mixture (Boehringer Mannheim) as
described in [24]. The DNA was denatured for
2 min at 94‡C prior to each PCR cycle (17^40 cycles)
of 94‡C for 1 min, each annealing temperature (50^
62‡C) for 1 min, 72‡C for 1 min, followed by 4 min
at 72‡C before refrigeration. The primers employed
are listed here: caspase-1 (upstream) 5P-AAC CCA
GCT ATG CCC ACA TCC-3P ; caspase-1 (down-
stream) 5P-TTA ATG TCC TGG GAA GAG
GTA-3P ; caspase-2 (upstream) 5P-GTT ACC TGC
ACA CCG AGT CAC G-3P ; caspase-2 (down-
stream) 5P-GCG TGG TTC TTT CCA TCT TGT
TGG TCA-3P ; caspase-3 (upstream) 5P-GAA TAT
CCC TGG ACA ACA-3P ; caspase-3 (downstream)
5P-ACG CCA TGT CAT CAT CAA-3P ; caspase-4
(upstream) 5P-GGT CAT CAT TGT CCA GGC-3P ;
caspase-4 (downstream) 5P-CCA TTG TGC TGT
CTC TCC-3P ; caspase-5 (upstream) 5P-ACC ACA
TGC TAA AGA ACA-3P ; caspase-5 (downstream)
5P-CGA TTT GCA GAA GAG GTT-3P ; caspase-6
(upstream) 5P-ACC CGC AGG TTT TCA GA-3P ;
caspase-6 (downstream) 5P-CAT GAG CCG TTC
ACA GT-3P ; caspase-7 (upstream) 5P-AGC CTG
GGT TTT GAC GTG-3P ; caspase-7 (downstream)
5P-ACC GTG GAA TAG GCG AAG-3P ; caspase-
8 (upstream) 5P-GGA CTG CTT CAT CTG CTG-
3P ; caspase-8 (downstream) 5P-ATC TGT TTC CCC
ATG TTT-3P ; caspase-9 (upstream) 5P-TAA CAG
GCA AGC AGG AAA-3P ; caspase-9 (downstream)
5P-TCT TGG CAG TCA GGT CGC-3P ; caspase-10
(upstream) 5P-AGA AGT CCA GCT CAG CCT-3P ;
caspase-10 (downstream) 5P-ACT CGG CTT CCT
TGT CTA-3P ; glyceraldehyde 3-phosphate dehydro-
genase (GAPDH) (upstream) 5P-AAA CCC ATC
ACC ATC TTC CAG-3P ; and GAPDH (down-
stream) 5P-AGG GGC CAT CCA CAG TT TCT-
3P. The number of cycles selected for each primer
pair was found to produce a linear relationship be-
tween the input RNA and the resulting PCR prod-
ucts. The PCR products were analyzed on a 6.5%
non-denaturing polyacrylamide gel.
2.7. Western blot analysis
The cells were collected and suspended in 50 mM
Tris-HCl (pH 7.4), 137 mM NaCl, 2 mM EDTA,
1 mM PMSF, 10 Wg/ml aprotinin, and 10 Wg/ml leu-
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peptin. The cells were then sonicated and centrifuged
at 15 000 rpm for 20 min at 4‡C. The supernatants
(cytosol fractions) were used for the immunoblotting
of ICH-1L (caspase-2), CPP32 (caspase-3), and K-
tubulin and the pellet (membrane fractions) was
used for the immunoblotting of poly(ADP-ribose)
polymerase (PARP). For the immunoblotting of cy-
tochrome c, the cells were collected and suspended in
10 mM HEPES-NaOH (pH 7.4), 1 mM EDTA, and
250 mM sucrose and frozen in liquid nitrogen. After
thawing on ice, the cells were disrupted by douncing
10 times using a dounce homogenizer (Wheaton),
and the cells were then centrifuged at 2000Ug for
5 min at 4‡C. The supernatant was further centri-
fuged at 20 000Ug for 20 min at 4‡C, and the cytosol
fractions were used for immunoblotting. The indi-
cated amounts of protein were separated on 8^15%
SDS-polyacrylamide gels and transferred onto a ni-
trocellulose membrane. The following antibodies
were used as primary antibody: anti-human ICH-
1L polyclonal goat antibody (Santa Cruz), anti-hu-
man CPP32 monoclonal antibody (Transduction
Laboratories), anti-caspase-6, -7, -8, and -10, anti-
human cytochrome c monoclonal antibody
(7H8.2C12) (Pharmingen), anti-K-tubulin monoclo-
nal antibody (Seikagaku), and anti-human PARP
monoclonal antibody (Clontech). Either horseradish
peroxidase conjugated anti-mouse IgG (Amersham)
or horseradish peroxidase conjugated anti-goat IgG
(Santa Cruz) was used as the secondary antibody.
Detection of the bands was performed using the
ECL system (Amersham).
2.8. Preparation of S-100 fractions from SK-N-MC
cells
The cells were collected and suspended in bu¡er A
(20 mM HEPES-NaOH (pH 7.4), 10 mM KCl,
1.5 mM MgCl2, 1 mM EDTA, 1 mM EGTA,
1 mM DTT, 1 mM PMSF, 1 Wg/ml aprotinin). After
incubation on ice for 15 min, the cells were homo-
genized and centrifuged at 2000Ug for 10 min at
4‡C. The supernatant was centrifuged at 20 000Ug
for 20 min at 4‡C and further centrifuged at
100 000Ug for 1 h at 4‡C. The resulting supernatant
(S-100 fraction) was stored at 380‡C and used for
the in vitro cleavage assay. The immunodepletion of
cytochrome c from SK-N-MC S-100 was carried out
using an anti-cytochrome c antibody (6H2.B4) that
recognized the native form of cytochrome c. 40 Wl of
this antibody were incubated with a 1:1 mixture of
50 Wl of protein A and protein G-Sepharose beads
(50% slurry) at 4‡C for 3 h. The beads were collected
and incubated with S-100 fractions for 12 h in a
rotator at 4‡C. The beads were subsequently pelleted
by centrifugation at 10 000Ug for 15 min at 4‡C. The
supernatant was used as cytochrome c-depleted
S-100.
2.9. In vitro cleavage assay
A cDNA encoding the full length of caspase-2 was
cloned into a pCR3.1 vector (Invitrogen). An in vitro
translation of caspase-2 was carried out using a TNT
T7 transcription/translation kit (Promega) in the
presence of [35S]methionine according to the instruc-
tions of the manufacturer. A 1 Wl aliquot of the in
vitro-translated caspase-2 was incubated with 50 Wg
of the above in the indicated fractions, 1 mM dATP
and 1 mM additional MgCl2 at 30‡C for 2 h in a
¢nal volume of 20 Wl of bu¡er A. At the end of the
incubation, 5 Wl of 5USDS bu¡er was added to each
reaction. After boiling for 5 min, each sample was
subjected to a 15% SDS-polyacrylamide gel and vis-
ualized by Fujix BAS 2000 (Fuji).
3. Results
3.1. Induction of apoptosis by ceramide
To investigate whether C2-ceramide induces the
loss of viability in SK-N-MC cells, we estimated
the LDH leakage as an index of cell death. Treat-
ment with C2-ceramide induced LDH leakage in a
dose-dependent manner (Fig. 1A). Furthermore, the
treatment also resulted in internucleosomal DNA
fragmentation (Fig. 1B) and chromatin condensation
(Fig. 1C), both of which are biochemically and mor-
phologically characteristic of apoptosis, suggesting
the cell death by C2-ceramide is apoptosis. Treat-
ment with 20 WM sphingosine, a sphingolipid break-
down product, also caused internucleosomal DNA
fragmentation and morphological changes character-
istic of apoptotic cells (Fig. 1B,C). To investigate the
speci¢city of C2-ceramide-induced phenomena on
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apoptosis, we tested the e¡ect of a structural ana-
logue of ceramide. A ceramide analogue C2-dihydro-
ceramide (DHC2-ceramide), which lacks the C4-5
trans double bond in the sphingolipid backbone nec-
essary for the biological e¡ects of ceramide [25], in-
duces neither LDH leakage (Fig. 1A) nor character-
istic changes in apoptosis (Fig. 1B,C). Furthermore,
the addition of 20 WM sphingosine-1 phosphate, a
metabolic product of sphingosine, also did not in-
duce DNA fragmentation (Fig. 1B). On the other
Fig. 1. Induction of apoptosis by C2-ceramide in SK-N-MC cells. (A) LDH leakage caused by C2-ceramide and C2-dihydroceramide
(DHC2-ceramide). The cells were treated with the indicated concentrations (0^20 WM) of C2-ceramide or 20 WM DHC2-ceramide for
24 h and then subjected to an LDH leakage assay. Each value is the mean þ S.E. of three samples. (B) DNA fragmentation by treat-
ment with ethanol vehicle (lane 1), 20 WM C2-ceramide (lane 2), 20 WM sphingosine (lane 3), 400 mU/ml SMase (lane 4), 20 WM
DHC2-ceramide (lane 5), and 20 WM sphingosine-1-P (lane 6) for 6 h. (C) Nuclear staining of cells with the £uorescent dye Hoechst
33258 after treatment with ethanol vehicle (panel 1), 20 WM C2-ceramide (panel 2), 20 WM sphingosine (panel 3), and 20 WM DHC2-
ceramide (panel 4) for 6 h.
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hand, sphingomyelinase (SMase) catalyzes the hy-
drolysis of sphingomyelin, yielding ceramide. It has
been reported that treatment with exogenous SMase
increases the levels of intracellular ceramide and sub-
sequently induces apoptosis in human leukemia cell
lines HL-60 and U937 [26]. In SK-N-MC cells, the
addition of 400 mU/ml of exogenous bacterial SMase
induced LDH leakage (data not shown) and internu-
cleosomal DNA fragmentation (Fig. 1B).
3.2. The involvement of caspases in ceramide-induced
apoptosis
Caspases have been shown to be implicated in var-
ious kinds of agent-induced apoptosis. To elucidate
the involvement of caspases in C2-ceramide-induced
apoptosis in SK-N-MC cells, we examined the e¡ect
of Z-Asp-CH2-DCB, a caspase inhibitor, on C2-cer-
amide-induced internucleosomal DNA fragmenta-
tion. Pretreatment with Z-Asp-CH2-DCB inhibited
not only internucleosomal DNA fragmentation by
C2-ceramide (Fig. 2A) but also exogenous SMase-
mediated internucleosomal DNA fragmentation
(data not shown) in a dose-dependent manner. Fur-
thermore, we investigated whether PARP is cleaved
by treatment with C2-ceramide, since PARP is a tar-
get of proteolytic cleavage by the caspases. Treat-
ment with C2-ceramide, but not DHC2-ceramide,
resulted in PARP cleavage, and the cleavage was
inhibited by pretreatment with Z-Asp-CH2-DCB in
a dose-dependent manner (Fig. 2B). Subsequently, to
investigate whether caspase activity increases in re-
sponse to C2-ceramide, cytosolic extracts from C2-
ceramide- or DHC2-ceramide-treated SK-N-MC
cells were subjected to a protease activity assay using
£uorogenic peptide substrates, DEVD-MCA and
YVAD-MCA. Enzymatic cleavage of DEVD-MCA,
which is speci¢c to caspase-3-like proteases, slightly
increased 3 h after the addition of C2-ceramide, and
thereafter became elevated for up to 6 h in a caspase
inhibitor-sensitive manner (Fig. 3A). On the other
hand, we detected no enzymatic cleavage of
Fig. 2. Involvement of caspases in C2-ceramide-induced apoptosis in SK-N-MC cells. (A) Inhibition of C2-ceramide-induced DNA
fragmentation by Z-Asp-CH2-DCB, a non-selective caspase inhibitor. The cells were preincubated with various concentrations of Z-
Asp-CH2-DCB (0^100 WM) for 1 h and then incubated with 20 WM C2-ceramide for 6 h. Genomic DNAs were subjected to a DNA
fragmentation assay. (B) Cleavage of PARP by treatment with C2-ceramide in SK-N-MC cells. The cells were pretreated with 100
WM Z-Asp-CH2-DCB for 1 h before treatment with C2-ceramide for 6 h (B) or treated with 20 WM C2-ceramide for various periods
(0^12 h) (A), and the membrane fractions (5 Wg) were subjected to Western blot analysis using anti-PARP antibody.
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YVAD-MCA, which is speci¢c to caspase-1-like pro-
tease activity, during C2-ceramide-induced apoptosis
(Fig. 3A). Treatment with DHC2-ceramide did not
induce the enzymatic cleavage of DEVD-MCA (Fig.
3A) or internucleosomal DNA fragmentation (Fig.
1B). We further examined VDVAD-AFC and
LEHD-AFC cleaving activity, speci¢c for caspase-2
and caspase-9, respectively. Enzymatic cleavage of
VDVAD-AFC was signi¢cantly detected 3 h after
being challenged with C2-ceramide, and was elevated
with a time course similar to that of the cleavage of
DEVD-MCA (Fig. 3B). LEHD-AFC cleavage was
slightly detected as early as 2 h after treatment
with C2-ceramide, and became thereafter elevated
as seen in those of other substrates (Fig. 3B).
We next investigated which isoforms of caspases
are expressed in SK-N-MC cells by RT-PCR meth-
ods. Total RNA was prepared from untreated and
C2-ceramide-treated SK-N-MC cells and analyzed by
qualitative RT-PCR (Fig. 4A). Caspases-2, -3, -4, -6,
-7, -8, -9, and -10 but not caspases-1 and -5 were
expressed in SK-N-MC cells. No signi¢cant di¡eren-
ces in the expression levels of the eight caspase family
members were observed between untreated and C2-
ceramide-treated cells.
We then examined which isoforms of caspases
were activated during apoptosis by C2-ceramide us-
ing antibodies speci¢c to each caspase. Immunoblot-
ting analysis revealed that proforms of caspases-2
and -3 decreased in C2-ceramide-treated cells in a
time-dependent manner (Fig. 4B). On the other
hand, caspases-6, -7, and -8 were detected in a qui-
escent state in SK-N-MC cells; however, the levels of
these proteins did not change during apoptosis (Fig.
4B). The level of K-tubulin, used as an internal con-
trol, was not altered by treatment with C2-ceramide
(Fig. 4B).
3.3. The release of cytochrome c into the cytosol
during ceramide-induced apoptosis
Cytochrome c, which is released from mitochon-
dria, has recently been identi¢ed as a key or impor-
tant factor that can activate caspase-3 in a cell-free
system [27]. In fact, it has been reported that levels of
cytosolic cytochrome c are increased in response to
various apoptotic stimuli such as staurosporine, eto-
poside, and ultraviolet-B irradiation [28,29]. We
therefore tested whether levels of cytosolic cyto-
chrome c increase in response to C2-ceramide. Cyto-
Fig. 3. Activation of caspases during apoptosis induced by C2-ceramide. (A) Activation of caspase-3-like, but not caspase-1-like pro-
teases during C2-ceramide-induced apoptosis. The cells pretreated with or without Z-Asp-CH2-DCB for 1 h were incubated with 20
WM C2-ceramide or 20 WM DHC2-ceramide for the various indicated periods. Released AMC from the £uorogenic substrates Ac-
DEVD-AMC or Ac-YVAD-AMC were measured. a, 20 WM C2-ceramide (DEVD); b, 20 WM C2-ceramide+100 WM Z-Asp-CH2-
DCB (DEVD); O, 20 WM C2-ceramide (YVAD); E, 20 WM DHC2-ceramide (DEVD). Data are representative of three experiments.
(B) Time course for caspase-2 and -9 activity in the cell extracts after C2-ceramide challenge. The cells were stimulated with 20 WM
C2-ceramide for various periods. Then, cell lysates were prepared and an aliquot (200 Wg) was used for caspase-2 or -9 assay. Com-
parison of the £uorescence of AFC from a sample with an unstimulated sample allows determination of the fold increase in caspase
activity. Data are the mean of triplicate reactions run in parallel.
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chrome c in the cytosol fraction increased signi¢-
cantly after 2 h of being challenged with C2-ceram-
ide, and this increase was detected for up to 12 h
(Fig. 5). The time course of cytochrome c release
into the cytosol fractions by treatment with C2-cer-
amide was coincident with that of enzymatic LEHD-
AFC cleavage.
3.4. Cytochrome c activated caspase-2 in cell-free
system
Although cytochrome c can activate caspase-9 in
the presence of dATP and Apaf-1 (a human homo-
logue of Ced-4) in a cell-free system [30], it is not
known whether other caspases including caspase-2
can be activated by this cascade. We therefore exam-
ined the relationship between cytochrome c release
and caspase-2 activation. The S-100 fraction of cyto-
sol prepared from SK-N-MC cells contains a small
amount of cytochrome c by homogenization (Fig.
6A). To remove the contaminated and leaked cyto-
chrome c, a monoclonal antibody against cyto-
chrome c was added into the S-100 fraction (desig-
nated S-100 (3cyt c)) (Fig. 6A). As shown in Fig.
Fig. 5. Cytochrome c translocation to the cytoplasm induced by
treatment with C2-ceramide. The cells were treated with 20 WM
C2-ceramide for various periods (0^12 h), and the cytosol frac-
tions (10 Wg) were subjected to Western blot analysis using
anti-cytochrome c antibody.
Fig. 4. Caspase mRNA expression and protein level during
apoptosis. (A) Total RNA was isolated from ethanol vehicle
(lane 1) and 20 WM C2-ceramide-treated (lane 2) SK-N-MC
cells. RNA from Jurkat cells (lane 3) was used as a positive
control. The analysis in lane 4 was carried out without a
cDNA template as a negative control. Decrease of pro-caspase-
2 and -3 in response to C2-ceramide in SK-N-MC cells. The
cells were treated with 20 WM C2-ceramide for various periods
(0^12 h). (B) The cytosol fractions were prepared, and an ali-
quot (20 Wg) was then subjected to Western blot analysis using
anti-ICH-1L (caspase-2), anti-CPP32 (caspase-3), anti-caspase-6,
-7, and -8, and anti-K-tubulin antibodies.
6
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6B, the S-100 fraction could activate caspase-2 in the
presence of dATP, as measured by the cleavage of
pro-caspase-2. The S-100 (3cyt c) fraction lost the
ability to activate caspase-2, and the activation was
restored by the addition of puri¢ed cytochrome c
(Fig. 6B).
4. Discussion
We have shown that C2-ceramide, a cell-permeable
ceramide analogue, elicits apoptotic cell death as es-
timated by LDH leakage, internucleosomal DNA
fragmentation, and chromatin condensation in SK-
N-MC cells (Fig. 1). SMase, which hydrolyzes sphin-
gomyelin to ceramide, also induced LDH leakage
(data not shown) and DNA fragmentation (Fig.
1B), suggesting that the production of ceramide
from sphingomyelin with the addition of SMase
into the medium participates in the induction of
apoptosis in SK-N-MC cells. We found that sphin-
gosine, a metabolic product of ceramide, also induces
several apoptotic features in this cell line along with
caspase-3-like protease activation in a caspase inhib-
itor-sensitive manner (Fig. 1, data not shown), indi-
cating that sphingosine has the ability to induce
apoptosis as well as C2-ceramide in SK-N-MC cells.
Therefore, it is likely that sphingosine functions as a
second messenger in apoptosis. Alternatively, the in-
tracellular production of sphingosine may contribute
to apoptosis in response to ceramide. These results
are supported by previous reports that C2-ceramide
induces apoptosis in other cells, including neuronal
cells [1^6]. In contrast, it has been reported that C2-
ceramide protects against glutamate and amyloid
L-peptide toxicity or trophic factor deprivation-medi-
ated apoptosis [7,8], suggesting that the mechanism
of signal transduction after ceramide production dif-
fers among the di¡erent types of neuronal cell lines.
On the other hand, Hofmann and Dixit questioned
the role of ceramide in apoptosis [31]. They question
the existence of agonist-induced changes in sphingo-
lipid levels and speci¢cally challenge the use of the
diglyceride kinase (DGK) assay for quantitation of
ceramide, basing their argument on the results ob-
tained by Watts et al. [32]. Hereafter, some papers
objected to these assertions. Kolensnick and Hannun
[33] mentioned the failure to include all pertinent
data or misinterpretation of existing data and sug-
gested that ceramide functions as a transducer of
signals in a generalized stress-response pathway.
They also reported that the appropriate use of
DGK is critical for quanti¢cation of ceramide [34].
In response, Hofmann and Dixit [35], and Watts et
al. [36] took objection to the comments. In view of
these comments, the role of ceramide in apoptosis
Fig. 6. In vitro reconstitution of caspase-2 activation reaction
by cytochrome c. (A) Immunoblot analysis of cytochrome c
from a sample (30 Wg) of the S-100 fraction prepared from SK-
N-MC cells (S-100) (lane 1), the S-100 fraction immunodepleted
of cytochrome c (S-100 (3cyt c)) (lane 2), or S-100 (3cyt c)
plus 0.2 Wg of cytochrome c from horse heart (S-100 (3cyt
c)+cyt c) (lane 3). (B) Samples (50 Wg) of S-100, S-100 (3cyt c),
or S-100 (3cyt c)+cyt c were incubated for 2 h with in vitro-
translated 35S-labeled caspase-2 in the presence of 1 mM dATP.
Samples were subjected to 15% SDS-PAGE and analyzed by
Fujix Bas 2000. Anti-Fas antibody-treated Jurkat cytosolic ly-
sates (Jurkat lysates) were used as a positive control.
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remains controversial, because the quanti¢cation as-
say of ceramide is not yet fully established now. At
least, some stresses such as heat shock, cytokine (in-
cluding TNF-K), or hypoxia seem to increase the
levels of ceramide during apoptosis. Therefore, we
focus on the possible mechanism of apoptosis chal-
lenged with ceramide in this report.
Although the mechanism of ceramide-induced
apoptosis is not clearly understood, it is thought
that caspase-3 may be involved in apoptosis triggered
by ceramide [16,21]. In SK-N-MC cells, pretreatment
with a caspase inhibitor, Z-Asp-CH2-DCB, signi¢-
cantly suppressed C2-ceramide-induced DNA frag-
mentation in a dose-dependent manner (Fig. 2A).
Moreover, C2-ceramide, but not DHC2-ceramide,
resulted in PARP cleavage, yielding an 85 kDa frag-
ment showing typical caspase activity in a time- and
caspase inhibitor-dependent manner (Fig. 2B). Sub-
sequently, we tried to elucidate the subtypes of casp-
ase which may be involved in ceramide-induced
apoptosis. Caspase-3-like proteases, but not casp-
ase-1-like proteases, were activated during apoptosis
in response to C2-ceramide, and the activation was
sensitive to Z-Asp-CH2-DCB (Fig. 3A). On the other
hand, DHC2-ceramide, a structural ceramide ana-
logue with no biological e¡ects, could not elicit either
DNA fragmentation (Fig. 1B) or caspase-3-like pro-
tease activation (Fig. 3A). Furthermore, caspase-2
activity (VDVAD-AFC cleaving activity) was signi¢-
cantly detected with a time course as seen in that of
caspase-3-like proteases activation (Fig. 3B).
Although caspase-9 activity (LEHD-AFC cleaving
activity) also increased in response to C2-ceramide,
the activity was detected as early as 2 h after treat-
ment (Fig. 3B). These results suggest that caspases
including caspases-9, -2, and caspase-3-like proteases
are probably involved in C2-ceramide-induced apop-
tosis. Western blot analysis showed that the level of
pro-caspase-3 is decreased (Fig. 4B). These data are
consistent with results showing that caspase-3, but
not caspase-1, plays a key factor in various kinds
of stimulus-mediated apoptosis [16,17,20^22]. We
next examined whether the level of pro-caspase-2 is
really decreased by treatment with C2-ceramide cor-
responding to the results of enzymatic £uorescent
substrate cleavage. Fig. 4B shows that the level of
pro-caspase-2 is decreased in response to C2-ceram-
ide, suggesting the possibility that caspase-2 is also
activated during ceramide-induced apoptosis. Recent
reports have indicated that caspase-2 is an e¡ector in
the pathway leading to apoptosis induced by a vari-
ety of apoptotic stimuli such as etoposide, Q-irradia-
tion, nitric oxide, hypoxia or trophic factor with-
drawal [15,37^39]. We showed that caspase-2 may
be involved in apoptosis in response to ceramide in
SK-N-MC cells. However, further study is required
to clarify the role of caspase-2 in ceramide-induced
apoptosis.
Cytochrome c has recently been identi¢ed as one
factor that activates caspase-9 in collaboration with
Apaf-1 (a human homologue of Ced-4) and dATP
[27,30,40]. In fact, the release of mitochondrial cyto-
chrome c into cytosol is induced by apoptosis-elicit-
ing agents or the overexpression of Bax
[28,29,37,38,41]. We therefore examined whether cy-
tochrome c is released into the cytosol during ceram-
ide-induced apoptosis in SK-N-MC cells. As shown
in Fig. 5, cytochrome c was detected in the cytosol
fractions 2 h after C2-ceramide treatment. The ap-
pearance of cytosolic cytochrome c in response to
C2-ceramide precedes the decrease of caspase-2 and
-3 proforms, and increase in DEVD-MCA and
VDVAD-AFC cleaving activity. However, both cy-
tochrome c release into cytosol fraction and caspase-
9 activation (LEHD-AFC cleavage) were detected as
early as 2 h after treatment. These results suggest
that cytochrome c release and caspase-9 activation
lead to caspase-2 and -3 activation. Therefore, to
investigate whether caspase-2 acts downstream from
cytochrome c release the same as caspase-3, we ex-
amined the roles of cytochrome c on caspase-2 acti-
vation using a cell-free system. The examination us-
ing S-100 fractions prepared from SK-N-MC cells
indicated that the activation of caspase-2 was in-
duced by the addition of cytochrome c (Fig. 6).
This suggested that cytochrome c may be able to
activate caspase-2 either directly or indirectly. Casp-
ase-2 is thought to be probably activated by caspase-
3-like activity [42]. Therefore, caspase-2 may be acti-
vated by other caspases including caspase-3 by treat-
ment with C2-ceramide in SK-N-MC cells as seen in
Fas- or staurosporine-induced apoptosis [42].
Although we showed evidence that the proform of
caspase-2 is decreased by treatment with C2-ceram-
ide (possibly in a cytochrome c-dependent manner),
there remains the problem of how caspase-2 is acti-
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vated by the treatment in neuronal cells. Wang et al.
have shown that cytochrome c activates caspase-3
through the formation of the caspase-9/Apaf-1 com-
plex, and the physical association of caspase-9 and
Apaf-1 is mediated by the interaction of their respec-
tive caspase recruitment domains (CARDs) [40]. Sev-
eral other caspases, including caspases-1, -2, -4, -8,
and -10, also contain a CARD-like domain in their
NH2 termini. Moreover, it has been reported that
caspases-4 and -8 can associate with Apaf-1 through
their respective CARDs [43]. We have shown that
caspase-9 is activated by C2-ceramide in SK-N-MC
cells (Fig. 4B). Hence, it appears possible that (1)
cytochrome c directly activates caspase-2 through
the putative adaptor protein which has a CARDs
in its NH2 terminus, as seen in caspase-9 activation,
or (2) the activation of caspase-9 by the formation of
the caspase-9/Apaf-1 complex which sequentially
cleaves pro-caspase-2 either directly or indirectly.
In conclusion, we have demonstrated that C2-cer-
amide, a cell-permeable ceramide analogue, induces
apoptosis accompanying the release of cytochrome c
into the cytosol and activation of caspases-2, -3, and
-9 in SK-N-MC cells. Our data show that the acti-
vation of caspase-2 is triggered by the addition of
cytochrome c in lysates of SK-N-MC cells. In view
of these results, the release of cytochrome c into the
cytosol and the sequential activation of caspases-9,
-3, and -2 may be partly implicated in ceramide-in-
duced apoptosis in SK-N-MC cells.
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